Navigation Links
FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
Date:7/29/2013

NEWARK, Calif., July 29, 2013 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) announced today that the U. S. Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Mallinckrodt (NYSE: MNK) for MNK-795.  MNK-795 is a controlled-release oral formulation of oxycodone and acetaminophen that has been studied for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.  MNK-795 is formulated with Depomed's Acuform® drug delivery technology.      

The NDA acceptance triggers a $5 million milestone payment to Depomed under a license agreement between Depomed and Mallinckrodt.  Depomed is also entitled to an additional milestone payment upon approval of the NDA and high single digit royalties on net sales of MNK-795, if approved.

The FDA granted the NDA a priority review, a designation given to drugs that, if approved, offer significant improvements in the safety or effectiveness of the treatment when compared to standard applications. 

"We are pleased that the FDA has accepted the NDA for MNK-795 for filing, and we look forward to potential approval of this product," said Jim Schoeneck, President and CEO of Depomed.  "Depomed's proprietary Acuform drug-delivery technology is also being used (under similar milestone and royalty terms) by Mallinckrodt in development of another pipeline product that is being studied in patients with acute, moderate to severe pain.  Should either or both of these products be approved, we believe that the combination of milestones and royalties on net sales can make a significant contribution to Depomed's future revenues."

About Depomed
Depomed
'/>"/>

SOURCE Depomed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... BEDFORD, Mass., July 30, 2014  Hologic, Inc. (NASDAQ: ... the third fiscal quarter ended June 28, 2014. ... , Revenues increased 1.0% to $632.6 million, reflecting operational ... 0.5%, compared to the same period in the prior ... four business segments. , Breast Health revenues grew 3.5%. ...
(Date:7/30/2014)... -- CryoLife, Inc. (NYSE: CRY), a leading medical device ... surgery, announced today that its Board of Directors has ... 2014 of $0.03 per share of common stock outstanding.  ... be paid on September 19, 2014 to all common ... ex-dividend date for the quarterly dividend is September 10, ...
(Date:7/30/2014)... , July 30, 2014  Unilife Corporation ("Unilife" ... a developer and supplier of injectable drug delivery ... manufacturing capacity, R&D, and facilities in response to ... its products and services. During the fourth quarter ... $16 million in capital expenditures and R&D above ...
Breaking Medicine Technology:Hologic Announces Third Quarter Fiscal 2014 Operating Results 2Hologic Announces Third Quarter Fiscal 2014 Operating Results 3Hologic Announces Third Quarter Fiscal 2014 Operating Results 4Hologic Announces Third Quarter Fiscal 2014 Operating Results 5Hologic Announces Third Quarter Fiscal 2014 Operating Results 6Hologic Announces Third Quarter Fiscal 2014 Operating Results 7Hologic Announces Third Quarter Fiscal 2014 Operating Results 8Hologic Announces Third Quarter Fiscal 2014 Operating Results 9Hologic Announces Third Quarter Fiscal 2014 Operating Results 10Hologic Announces Third Quarter Fiscal 2014 Operating Results 11Hologic Announces Third Quarter Fiscal 2014 Operating Results 12Hologic Announces Third Quarter Fiscal 2014 Operating Results 13Hologic Announces Third Quarter Fiscal 2014 Operating Results 14Hologic Announces Third Quarter Fiscal 2014 Operating Results 15Hologic Announces Third Quarter Fiscal 2014 Operating Results 16Hologic Announces Third Quarter Fiscal 2014 Operating Results 17CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 2CryoLife Announces Quarterly Cash Dividend for the Third Quarter 2014 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 2Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 3Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 4Unilife Accelerates Investment to Meet Increasing Demand from New and Existing Customers 5
... Lexicon Pharmaceuticals, Inc. (Nasdaq: ... new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated ... of non-constipating irritable bowel syndrome (IBS). Top-line results ... times daily produced a statistically significant improvement in global ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer of ... first fiscal quarter ended September 30, 2009, compared with $2,001,896 ... 2.2%. , The first quarter of fiscal 2010 produced operating ... for the first quarter of fiscal 2009. The net loss ...
Cached Medicine Technology:Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 2Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 3Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 4Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome 5Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3
(Date:7/31/2014)... 31, 2014 Reputation Management India, a ... service named ‘Remove Bad Reviews’. The service is for ... published on various review sites. , The company ... internet marketing, the sites that allow bad reviews, and ... to tailor the service. , About the service, ...
(Date:7/31/2014)... Thousands of independent community pharmacists, ... have come together today to kick off ThoughtSpot ... , "ThoughtSpot 2014 is Good Neighbor Pharmacy’s annual ... to help their businesses thrive," stated AJ Caffentzis, ... long-standing commitment to independent community pharmacies, and at ...
(Date:7/31/2014)... July 31, 2014 T.E.N., a ... firm, honored finalists and winners Wednesday evening, July ... and Awards Gala at the Westin St. Francis ... of information security for the BlackLine Systems, was ... Year Award winner for the ISE® West Region. ...
(Date:7/31/2014)... HealthDay Reporter WEDNESDAY, July 30, ... disease can often be cured with a stem cell transplant, ... a new study finds. Severe combined immunodeficiency (SCID), as ... of rare genetic disorders that all but eliminate the immune ... The term "bubble boy" became popular after a Texas ...
(Date:7/31/2014)... time after surgery may be reduced for patients taking ... new study. The study,s Irish researchers suspect that ... the amount of time surgical patients, wounds need to ... people who tend to have healing complications. "Statins ... in the world. While they are typically used to ...
Breaking Medicine News(10 mins):Health News:Reputation Management India Launches a New Service Called ‘Remove Bad Reviews’ 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 2Health News:Good Neighbor Pharmacy’s ThoughtSpot Begins Today with Record Attendance 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 2Health News:Early Stem Cell Transplant Vital in 'Bubble Boy' Disease 3Health News:Cholesterol Drugs May Speed Healing After Surgery 2
... genital warts, is also held responsible for almost 75% of ... diagnosed with cervical cancer and one-third of them succumb to ... Gardsil have been developed which has been proved effective in ... HPV virus thus also in the bigger perspective gives ...
... option that can work like a magic potion to counter ... stroke or cerebro// vascular accident(CVA). ,According to the ... mice, revealed that a compound called Resveratrol found ... doses, showed remarkable effect in reducing brain damage in ...
... the risk of atherosclerosis in diabetics may be decreased ... thickening and hardening of artery walls. 80% of the ... ,This study, conducted by researchers at the Technion-Israel Institute ... the risk of developing atherosclerosis in people who drank ...
... despite the fact that few actually need it, says a ... stay healthy is a balanced diet. ,People are often ... fewer nutrients than it used to, said Jane Clarke. The ... reported the online edition of Daily Mail. ...
... and depend on which state, city or individual hospital ... new report//. ,The report, HealthGrades Hospital Quality in ... lower risk of dying at "5-star" hospitals compared with ... best- and worst-performing hospitals has in fact widened by ...
... susceptibility to autism is increased with a single gene mutation ... ,This discovery has far-reaching implications because this gene, a variant ... a brain gene but rather a gene which has its ... function and gut repair. ,Therefore researchers have concluded ...
Cached Medicine News:Health News:Balanced Diet is Better than Vitamin Pills 2Health News:Hospital Outcome Linked to its Quality 2Health News:Risk of Autism doubled with Single Gene Mutation 2
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
The ACCU-Beam® line of Surgical Microscope Accessories includes digital camera adaptors, beam splitters, objective lenses, fiber optic cables, and fiberoptic retrofits....
Medicine Products: